Posted by Michael Wonder on 14 Dec 2024
Roche’s Vabysmo pre-filled syringe approved in the EU for three retinal conditions that can cause blindness
13 December 2024 - Vabysmo PFS is the first and only pre-filled syringe containing a bi-specific antibody, offering a convenient alternative to currently available Vabysmo vials.
Roche announced today that the EMA has approved Vabysmo (faricimab) 6.0 mg single-dose pre-filled syringe for use in the treatment of neovascular or ‘wet’ age-related macular degeneration, diabetic macular oedema and macular oedema following retinal vein occlusion.
